Aortic Repair Device Market by Type (Endovascular Stent Graft, Open Surgical Graft), Material (Dacron, PTFE), End User, Application - Global Forecast 2025-2032
Description
The Aortic Repair Device Market was valued at USD 3.06 billion in 2024 and is projected to grow to USD 3.32 billion in 2025, with a CAGR of 9.21%, reaching USD 6.21 billion by 2032.
A concise strategic overview of the aortic repair device landscape capturing clinical innovation, regulatory complexities and commercial imperatives for executive audiences
The aortic repair device landscape sits at the intersection of rapid clinical innovation, evolving regulatory expectations, and rising demand for less invasive therapeutic pathways. Clinicians are increasingly prioritizing approaches that reduce perioperative morbidity and shorten hospital stays, prompting medical device development to concentrate on refined endovascular solutions and durable graft materials. At the same time, payers and health systems are scrutinizing value propositions, favoring interventions that demonstrate clear improvements in patient throughput and long-term outcomes. This dynamic creates both pressure and opportunity for manufacturers, health systems, and investors to align product development, clinical evidence generation, and commercialization strategies.
Recent advances in imaging, delivery systems, and graft materials have expanded procedural options for patients with abdominal and thoracic aortic pathologies, and these technological trajectories are complemented by procedural refinements and enhanced perioperative protocols. Concurrently, supply chain resilience, sourcing strategies for polymers and textile graft components, and international trade policies have begun to influence lead times and procurement practices. As a result, strategic planning now requires an integrated view that connects clinical effectiveness with manufacturing agility, regulatory readiness, and payer engagement. The following analysis synthesizes these considerations to inform executive decision-making across the device lifecycle.
Accelerating clinical, technological and commercial shifts reshaping aortic repair devices that compel strategic realignment across R&D, supply chain and clinical adoption pathways
The aortic repair field is experiencing transformative shifts driven by converging technological, clinical, and commercial forces. Minimally invasive techniques and refinements in endovascular delivery systems are extending the range of patients eligible for less invasive interventions, reshaping referral pathways and procedural volumes. New imaging modalities and procedural planning tools have improved patient selection and device sizing, which in turn reduces complications and supports broader adoption by vascular surgeons and interventionalists.
Material science advances are producing graft textiles and coatings that aim to balance long-term durability with reduced thrombogenicity and improved endothelial integration. These innovations matter not only for device performance but also for regulatory strategy and reimbursement positioning, since incremental product improvements require robust clinical evidence to justify premium pricing and formulary inclusion. Parallel changes in hospital operations and ambulatory surgical center models emphasize throughput efficiency and cost containment, incentivizing devices that enable shorter stays and predictable recovery trajectories. Collectively, these shifts are redefining R&D priorities, competitive differentiation, and the types of clinical partnerships that yield sustained market advantage.
Comprehensive assessment of how evolving United States tariff measures in 2025 are reshaping supply chains, procurement strategies and competitive positioning in the device landscape
The emergence of tariff measures and trade policy adjustments in 2025 has introduced an additional layer of complexity into the global supply chains that support aortic repair device production and distribution. Tariffs affecting critical inputs, such as polymers, textile graft substrates, and precision manufacturing components, influence sourcing decisions and inventory strategies. Manufacturers must weigh the trade-offs between onshoring production, relocating assembly operations, or diversifying suppliers to mitigate tariff exposure while preserving unit economics and time-to-market.
Procurement teams within hospital systems and ambulatory surgical centers are responding by seeking greater transparency around landed costs and lead-time variability. This has prompted a shift toward longer-term supplier agreements and dual-source strategies for high-risk components, which, in turn, influence contract negotiations and capital allocation for device makers. Regulatory alignment across jurisdictions also becomes more consequential as firms consider manufacturing relocations, given that quality systems, device registration pathways, and postmarket surveillance obligations must be reestablished or adapted to new production sites.
Competitive dynamics evolve as well; smaller innovative firms may face disproportionately higher operational burdens from incremental tariffs compared with larger incumbents that can absorb cost shifts or reconfigure global production footprints. Conversely, firms that proactively adjust commercial models-by offering service bundles, risk-sharing contracts, or localized manufacturing partnerships-can convert tariff-driven disruption into differentiation. Overall, tariff-driven pressures in 2025 necessitate a strategic reassessment of sourcing, pricing transparency, and collaborative procurement models to sustain supply continuity and customer trust.
Segment-driven strategic perspective revealing how device types, clinical applications, end users and graft materials determine adoption pathways, evidence needs and supply requirements
Understanding demand drivers requires a segmentation-informed lens that links device characteristics to clinical and operational contexts. Based on Type, market analysis separates Endovascular Stent Graft and Open Surgical Graft pathways; importantly, the Endovascular Stent Graft pathway is further examined across Aortomonoiliac, Bifurcated, and Cuff configurations, each presenting distinct delivery system requirements, sizing considerations, and inventory management implications. These subtype differences influence manufacturing complexity and capital intensity, and they shape clinical training needs as well as stocking decisions for hospitals and ambulatory surgical centers.
Based on Application, device selection aligns with clinical presentation across Abdominal Aortic Aneurysm, Aortic Dissection, and Thoracic Aortic Aneurysm, and each indication carries unique procedural risk profiles and imaging demands that affect device design and evidence-generation strategies. Procedural complexity and long-term follow-up requirements vary by application, which informs payer dialogues and value demonstration frameworks. Based on End User, the adoption environment diverges between Ambulatory Surgical Center and Hospital settings; ambulatory centers emphasize shortened recovery pathways and procedural efficiency, while hospitals focus on complex case management and integrated perioperative care teams, so commercial and training programs must be tailored accordingly. Based on Material, the choice between Dacron and PTFE underpins performance trade-offs related to handling characteristics, porosity, and long-term integration, thereby driving product positioning, clinical preference, and inventory segmentation.
Synthesizing these dimensions enables manufacturers and health systems to prioritize investment in device platforms that align with the most compelling clinical needs and operational realities. Translating segmentation insights into action requires coordinated strategies across R&D, clinical affairs, and commercial operations to ensure that product portfolios, training programs, and supply chain approaches match the differentiated requirements of each segment.
Regional drivers and cross-border considerations that influence adoption, reimbursement, and supply chain strategies across the Americas, Europe Middle East & Africa and Asia-Pacific markets
Regional dynamics exert powerful influence over reimbursement structures, clinical practice patterns, and supply chain logistics for aortic repair devices. In the Americas, healthcare systems vary from highly consolidated hospital networks to growth in outpatient procedural capacity, and reimbursement frameworks increasingly reward demonstrable outcomes and cost-effectiveness. This encourages devices that facilitate reduced length of stay and predictable procedural workflows. In Europe, Middle East & Africa, regulatory landscapes and payer systems differ markedly across countries, creating a mosaic of market entry requirements and reimbursement timelines; localized clinical evidence and region-specific partnerships prove essential for adoption, and logistical considerations around cross-border distribution and warehouse placement affect lead times and inventory levels.
In Asia-Pacific, rapid investments in interventional capability and an expanding base of trained specialists accelerate procedural uptake, but diversity in procurement practices and regulatory maturity across jurisdictions requires nuanced market access strategies. Furthermore, demographic trends and rising prevalence of vascular disease in several Asia-Pacific markets intensify demand for scalable solutions and support services. Across all regions, cross-border flows of components and finished devices mean that regional strategies must coordinate regulatory, manufacturing, and commercial activities to reduce friction. Consequently, manufacturers aiming to achieve global reach should prioritize adaptable product platforms, invest in regionally targeted clinical evidence, and design supply chains that balance centralization benefits with the agility required by local markets.
Strategic competitive intelligence on incumbents, innovators, and partnership-driven models that influence product advancement, clinical adoption and commercial scalability in the sector
Competitive dynamics in the aortic repair device ecosystem reflect a mix of established multinational manufacturers, specialized mid-sized firms, and innovative startups. Incumbent organizations typically leverage scale in manufacturing, established clinical relationships, and broad regulatory expertise to maintain wide distribution channels and to support long-term postmarket surveillance commitments. Specialized firms and startups contribute differentiated value by advancing graft materials, novel delivery mechanisms, and targeted solutions for specific anatomical challenges. Strategic partnerships, OEM arrangements, and co-development agreements are common pathways for transferring innovation from small teams to broader commercial platforms, enabling faster clinical adoption while distributing development risk.
Across the competitive landscape, companies increasingly pursue integrated value propositions that combine device technology with procedural support, training programs, and data analytics to demonstrate clinical outcomes and drive hospital adoption. Mergers and acquisitions remain a strategic tool for accessing new technologies and accelerating geographic expansion, while collaborative research agreements with academic medical centers continue to generate the clinical evidence required for premium positioning. As regulatory scrutiny tightens around long-term device performance, companies that invest early in robust postmarket data collection and transparent safety programs strengthen both clinician confidence and payer conversations. Overall, the environment favors organizations that balance innovation speed with regulatory diligence and commercial execution.
Actionable, prioritized strategic recommendations for device makers, hospital systems and supply chain leaders to accelerate innovation adoption and optimize commercial impact
Leaders seeking to strengthen their position in the aortic repair device sector should act on a set of prioritized recommendations that align R&D, clinical, and commercial activities. First, integrate clinical evidence planning into product development from day one to ensure that device iterations produce the data clinicians and payers require for adoption and reimbursement. Second, design supply chains with modular redundancy and diversified sourcing for critical materials to mitigate tariff and component risk while maintaining cost predictability. Third, tailor go-to-market strategies to the operational realities of hospitals and ambulatory surgical centers by offering training, consumable management, and procedural optimization services that reduce administrative friction for purchasers.
Additionally, invest in material science and delivery system differentiation to target segments defined by anatomical complexity and comorbidity burden. Forge strategic collaborations with academic centers and specialized clinical networks to accelerate investigator-led trials and gather meaningful real-world evidence to support value propositions. Finally, adopt flexible commercial models that include outcome-based agreements and service elements to align incentives with healthcare providers and payers. Implementing these measures in a coordinated manner will help stakeholders convert innovation into sustainable clinical and commercial impact.
Transparent research methodology detailing evidence review, expert interviews, triangulation techniques and scenario analysis used to generate balanced insights for executives
The research approach underpinning this analysis combines systematic literature synthesis, expert interviews, and primary qualitative engagement with clinicians, supply chain leaders, and commercial stakeholders. Peer-reviewed clinical studies, regulatory filings, and procedural guidance documents were reviewed to establish an evidence baseline for device performance and clinical pathways. In parallel, structured interviews with vascular surgeons, interventional radiologists, procurement managers, and regulatory specialists provided context on adoption drivers, operational constraints, and regional market access considerations.
Data synthesis employed triangulation across sources to validate findings and reduce bias, and scenario analysis helped identify supply chain stress points and strategic response options. Throughout the process, analytic rigor was maintained by documenting data provenance, applying quality filters to source materials, and engaging external clinical advisors to review draft conclusions. Where primary quantitative metrics were relevant, descriptive analyses were used to contextualize qualitative insights without producing numerical forecasts. This methodology ensures that the resulting recommendations reflect a balanced, evidence-grounded perspective suitable for executive decision-making.
Concise synthesis of strategic imperatives and sector implications that equips executives to align R&D, supply chain and clinical strategies for durable competitive advantage
In synthesis, the aortic repair device sector is entering a period defined by incremental technological maturation, heightened commercial scrutiny, and more complex supply chain considerations. Minimally invasive approaches and material innovations offer clear clinical advantages, yet sustained adoption depends on credible, well-structured evidence programs and operational models that address hospital and ambulatory center needs. Regulatory and reimbursement environments will continue to shape product development priorities, and tariff or trade policy developments will require agile sourcing and manufacturing strategies.
Executives should view these developments as an opportunity to recalibrate priorities across R&D, clinical affairs, and commercial operations. Organizations that proactively align product design with clinical evidence generation, strengthen supply chain resilience, and offer services that reduce the adoption burden for providers will be better positioned to capture the benefits of evolving practice patterns. The imperative is clear: integrate clinical strategy, manufacturing flexibility, and payer engagement into a cohesive approach that turns innovation into measurable patient and system-level value.
Note: PDF & Excel + Online Access - 1 Year
A concise strategic overview of the aortic repair device landscape capturing clinical innovation, regulatory complexities and commercial imperatives for executive audiences
The aortic repair device landscape sits at the intersection of rapid clinical innovation, evolving regulatory expectations, and rising demand for less invasive therapeutic pathways. Clinicians are increasingly prioritizing approaches that reduce perioperative morbidity and shorten hospital stays, prompting medical device development to concentrate on refined endovascular solutions and durable graft materials. At the same time, payers and health systems are scrutinizing value propositions, favoring interventions that demonstrate clear improvements in patient throughput and long-term outcomes. This dynamic creates both pressure and opportunity for manufacturers, health systems, and investors to align product development, clinical evidence generation, and commercialization strategies.
Recent advances in imaging, delivery systems, and graft materials have expanded procedural options for patients with abdominal and thoracic aortic pathologies, and these technological trajectories are complemented by procedural refinements and enhanced perioperative protocols. Concurrently, supply chain resilience, sourcing strategies for polymers and textile graft components, and international trade policies have begun to influence lead times and procurement practices. As a result, strategic planning now requires an integrated view that connects clinical effectiveness with manufacturing agility, regulatory readiness, and payer engagement. The following analysis synthesizes these considerations to inform executive decision-making across the device lifecycle.
Accelerating clinical, technological and commercial shifts reshaping aortic repair devices that compel strategic realignment across R&D, supply chain and clinical adoption pathways
The aortic repair field is experiencing transformative shifts driven by converging technological, clinical, and commercial forces. Minimally invasive techniques and refinements in endovascular delivery systems are extending the range of patients eligible for less invasive interventions, reshaping referral pathways and procedural volumes. New imaging modalities and procedural planning tools have improved patient selection and device sizing, which in turn reduces complications and supports broader adoption by vascular surgeons and interventionalists.
Material science advances are producing graft textiles and coatings that aim to balance long-term durability with reduced thrombogenicity and improved endothelial integration. These innovations matter not only for device performance but also for regulatory strategy and reimbursement positioning, since incremental product improvements require robust clinical evidence to justify premium pricing and formulary inclusion. Parallel changes in hospital operations and ambulatory surgical center models emphasize throughput efficiency and cost containment, incentivizing devices that enable shorter stays and predictable recovery trajectories. Collectively, these shifts are redefining R&D priorities, competitive differentiation, and the types of clinical partnerships that yield sustained market advantage.
Comprehensive assessment of how evolving United States tariff measures in 2025 are reshaping supply chains, procurement strategies and competitive positioning in the device landscape
The emergence of tariff measures and trade policy adjustments in 2025 has introduced an additional layer of complexity into the global supply chains that support aortic repair device production and distribution. Tariffs affecting critical inputs, such as polymers, textile graft substrates, and precision manufacturing components, influence sourcing decisions and inventory strategies. Manufacturers must weigh the trade-offs between onshoring production, relocating assembly operations, or diversifying suppliers to mitigate tariff exposure while preserving unit economics and time-to-market.
Procurement teams within hospital systems and ambulatory surgical centers are responding by seeking greater transparency around landed costs and lead-time variability. This has prompted a shift toward longer-term supplier agreements and dual-source strategies for high-risk components, which, in turn, influence contract negotiations and capital allocation for device makers. Regulatory alignment across jurisdictions also becomes more consequential as firms consider manufacturing relocations, given that quality systems, device registration pathways, and postmarket surveillance obligations must be reestablished or adapted to new production sites.
Competitive dynamics evolve as well; smaller innovative firms may face disproportionately higher operational burdens from incremental tariffs compared with larger incumbents that can absorb cost shifts or reconfigure global production footprints. Conversely, firms that proactively adjust commercial models-by offering service bundles, risk-sharing contracts, or localized manufacturing partnerships-can convert tariff-driven disruption into differentiation. Overall, tariff-driven pressures in 2025 necessitate a strategic reassessment of sourcing, pricing transparency, and collaborative procurement models to sustain supply continuity and customer trust.
Segment-driven strategic perspective revealing how device types, clinical applications, end users and graft materials determine adoption pathways, evidence needs and supply requirements
Understanding demand drivers requires a segmentation-informed lens that links device characteristics to clinical and operational contexts. Based on Type, market analysis separates Endovascular Stent Graft and Open Surgical Graft pathways; importantly, the Endovascular Stent Graft pathway is further examined across Aortomonoiliac, Bifurcated, and Cuff configurations, each presenting distinct delivery system requirements, sizing considerations, and inventory management implications. These subtype differences influence manufacturing complexity and capital intensity, and they shape clinical training needs as well as stocking decisions for hospitals and ambulatory surgical centers.
Based on Application, device selection aligns with clinical presentation across Abdominal Aortic Aneurysm, Aortic Dissection, and Thoracic Aortic Aneurysm, and each indication carries unique procedural risk profiles and imaging demands that affect device design and evidence-generation strategies. Procedural complexity and long-term follow-up requirements vary by application, which informs payer dialogues and value demonstration frameworks. Based on End User, the adoption environment diverges between Ambulatory Surgical Center and Hospital settings; ambulatory centers emphasize shortened recovery pathways and procedural efficiency, while hospitals focus on complex case management and integrated perioperative care teams, so commercial and training programs must be tailored accordingly. Based on Material, the choice between Dacron and PTFE underpins performance trade-offs related to handling characteristics, porosity, and long-term integration, thereby driving product positioning, clinical preference, and inventory segmentation.
Synthesizing these dimensions enables manufacturers and health systems to prioritize investment in device platforms that align with the most compelling clinical needs and operational realities. Translating segmentation insights into action requires coordinated strategies across R&D, clinical affairs, and commercial operations to ensure that product portfolios, training programs, and supply chain approaches match the differentiated requirements of each segment.
Regional drivers and cross-border considerations that influence adoption, reimbursement, and supply chain strategies across the Americas, Europe Middle East & Africa and Asia-Pacific markets
Regional dynamics exert powerful influence over reimbursement structures, clinical practice patterns, and supply chain logistics for aortic repair devices. In the Americas, healthcare systems vary from highly consolidated hospital networks to growth in outpatient procedural capacity, and reimbursement frameworks increasingly reward demonstrable outcomes and cost-effectiveness. This encourages devices that facilitate reduced length of stay and predictable procedural workflows. In Europe, Middle East & Africa, regulatory landscapes and payer systems differ markedly across countries, creating a mosaic of market entry requirements and reimbursement timelines; localized clinical evidence and region-specific partnerships prove essential for adoption, and logistical considerations around cross-border distribution and warehouse placement affect lead times and inventory levels.
In Asia-Pacific, rapid investments in interventional capability and an expanding base of trained specialists accelerate procedural uptake, but diversity in procurement practices and regulatory maturity across jurisdictions requires nuanced market access strategies. Furthermore, demographic trends and rising prevalence of vascular disease in several Asia-Pacific markets intensify demand for scalable solutions and support services. Across all regions, cross-border flows of components and finished devices mean that regional strategies must coordinate regulatory, manufacturing, and commercial activities to reduce friction. Consequently, manufacturers aiming to achieve global reach should prioritize adaptable product platforms, invest in regionally targeted clinical evidence, and design supply chains that balance centralization benefits with the agility required by local markets.
Strategic competitive intelligence on incumbents, innovators, and partnership-driven models that influence product advancement, clinical adoption and commercial scalability in the sector
Competitive dynamics in the aortic repair device ecosystem reflect a mix of established multinational manufacturers, specialized mid-sized firms, and innovative startups. Incumbent organizations typically leverage scale in manufacturing, established clinical relationships, and broad regulatory expertise to maintain wide distribution channels and to support long-term postmarket surveillance commitments. Specialized firms and startups contribute differentiated value by advancing graft materials, novel delivery mechanisms, and targeted solutions for specific anatomical challenges. Strategic partnerships, OEM arrangements, and co-development agreements are common pathways for transferring innovation from small teams to broader commercial platforms, enabling faster clinical adoption while distributing development risk.
Across the competitive landscape, companies increasingly pursue integrated value propositions that combine device technology with procedural support, training programs, and data analytics to demonstrate clinical outcomes and drive hospital adoption. Mergers and acquisitions remain a strategic tool for accessing new technologies and accelerating geographic expansion, while collaborative research agreements with academic medical centers continue to generate the clinical evidence required for premium positioning. As regulatory scrutiny tightens around long-term device performance, companies that invest early in robust postmarket data collection and transparent safety programs strengthen both clinician confidence and payer conversations. Overall, the environment favors organizations that balance innovation speed with regulatory diligence and commercial execution.
Actionable, prioritized strategic recommendations for device makers, hospital systems and supply chain leaders to accelerate innovation adoption and optimize commercial impact
Leaders seeking to strengthen their position in the aortic repair device sector should act on a set of prioritized recommendations that align R&D, clinical, and commercial activities. First, integrate clinical evidence planning into product development from day one to ensure that device iterations produce the data clinicians and payers require for adoption and reimbursement. Second, design supply chains with modular redundancy and diversified sourcing for critical materials to mitigate tariff and component risk while maintaining cost predictability. Third, tailor go-to-market strategies to the operational realities of hospitals and ambulatory surgical centers by offering training, consumable management, and procedural optimization services that reduce administrative friction for purchasers.
Additionally, invest in material science and delivery system differentiation to target segments defined by anatomical complexity and comorbidity burden. Forge strategic collaborations with academic centers and specialized clinical networks to accelerate investigator-led trials and gather meaningful real-world evidence to support value propositions. Finally, adopt flexible commercial models that include outcome-based agreements and service elements to align incentives with healthcare providers and payers. Implementing these measures in a coordinated manner will help stakeholders convert innovation into sustainable clinical and commercial impact.
Transparent research methodology detailing evidence review, expert interviews, triangulation techniques and scenario analysis used to generate balanced insights for executives
The research approach underpinning this analysis combines systematic literature synthesis, expert interviews, and primary qualitative engagement with clinicians, supply chain leaders, and commercial stakeholders. Peer-reviewed clinical studies, regulatory filings, and procedural guidance documents were reviewed to establish an evidence baseline for device performance and clinical pathways. In parallel, structured interviews with vascular surgeons, interventional radiologists, procurement managers, and regulatory specialists provided context on adoption drivers, operational constraints, and regional market access considerations.
Data synthesis employed triangulation across sources to validate findings and reduce bias, and scenario analysis helped identify supply chain stress points and strategic response options. Throughout the process, analytic rigor was maintained by documenting data provenance, applying quality filters to source materials, and engaging external clinical advisors to review draft conclusions. Where primary quantitative metrics were relevant, descriptive analyses were used to contextualize qualitative insights without producing numerical forecasts. This methodology ensures that the resulting recommendations reflect a balanced, evidence-grounded perspective suitable for executive decision-making.
Concise synthesis of strategic imperatives and sector implications that equips executives to align R&D, supply chain and clinical strategies for durable competitive advantage
In synthesis, the aortic repair device sector is entering a period defined by incremental technological maturation, heightened commercial scrutiny, and more complex supply chain considerations. Minimally invasive approaches and material innovations offer clear clinical advantages, yet sustained adoption depends on credible, well-structured evidence programs and operational models that address hospital and ambulatory center needs. Regulatory and reimbursement environments will continue to shape product development priorities, and tariff or trade policy developments will require agile sourcing and manufacturing strategies.
Executives should view these developments as an opportunity to recalibrate priorities across R&D, clinical affairs, and commercial operations. Organizations that proactively align product design with clinical evidence generation, strengthen supply chain resilience, and offer services that reduce the adoption burden for providers will be better positioned to capture the benefits of evolving practice patterns. The imperative is clear: integrate clinical strategy, manufacturing flexibility, and payer engagement into a cohesive approach that turns innovation into measurable patient and system-level value.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
192 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Evolution of fenestrated and branched endografts for complex aortic aneurysm repair
- 5.2. Emergence of off-the-shelf branched endovascular aortic grafts for urgent thoracoabdominal cases
- 5.3. Integration of real-time intravascular ultrasound with 3d image fusion during tevar procedures
- 5.4. Advancements in polymer-based sealing systems to minimize endoleaks in endovascular repairs
- 5.5. Development of patient-specific 3d printed aortic stent grafts using ct angiography modeling
- 5.6. Implementation of ai-driven preoperative planning software to optimize graft sizing accuracy
- 5.7. Innovations in drug-eluting endografts aimed at reducing aortic wall inflammation and remodeling
- 5.8. Regulatory advances enabling accelerated fda breakthrough designation for novel aortic devices
- 5.9. Exploration of bioresorbable scaffold technologies for temporary aortic support and healing
- 5.10. Expansion of minimally invasive endovascular solutions addressing ascending aortic dissections
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Aortic Repair Device Market, by Type
- 8.1. Endovascular Stent Graft
- 8.1.1. Aortomonoiliac
- 8.1.2. Bifurcated
- 8.1.3. Cuff
- 8.2. Open Surgical Graft
- 9. Aortic Repair Device Market, by Material
- 9.1. Dacron
- 9.2. PTFE
- 10. Aortic Repair Device Market, by End User
- 10.1. Ambulatory Surgical Center
- 10.2. Hospital
- 11. Aortic Repair Device Market, by Application
- 11.1. Abdominal Aortic Aneurysm
- 11.2. Aortic Dissection
- 11.3. Thoracic Aortic Aneurysm
- 12. Aortic Repair Device Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Aortic Repair Device Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Aortic Repair Device Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. Artivion Inc
- 15.3.3. Becton Dickinson and Company
- 15.3.4. Bentley InnoMed GmbH
- 15.3.5. Biotronik SE & Co KG
- 15.3.6. Boston Scientific Corporation
- 15.3.7. Cardinal Health Inc
- 15.3.8. Cook Group Incorporated
- 15.3.9. CryoLife Inc
- 15.3.10. Edwards Lifesciences Corporation
- 15.3.11. Endologix LLC
- 15.3.12. Getinge AB
- 15.3.13. Johnson & Johnson
- 15.3.14. JOTEC GmbH
- 15.3.15. LeMaitre Vascular Inc
- 15.3.16. Lombard Medical Technologies plc
- 15.3.17. Medtronic plc
- 15.3.18. Merit Medical Systems Inc
- 15.3.19. MicroPort Scientific Corporation
- 15.3.20. Penumbra Inc
- 15.3.21. Shanghai MicroPort Endovascular MedTech Co., Ltd
- 15.3.22. Straub Medical AG
- 15.3.23. Stryker Corporation
- 15.3.24. Terumo Corporation
- 15.3.25. W. L. Gore & Associates Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
